Drug sensitivity reaction analysis method of patient-derived xenograft, analysis system and application thereof

Abstract

The invention discloses a drug sensitivity reaction analysis method of a patient-derived xenograft. The analysis method comprises the following steps: selecting a PDX (Patient-Derived Xenograft) drugsensitivity testing reaction mode; carrying out data quality control; counting and analyzing whether gross tumor volumes of different experiment arms have remarkable differences or not; comparing whether the experiment arms have differences with gross tumor volume growth curves of blank control groups; determining the drug sensitivity reaction grade of each testing mouse, and calculating the drugeffect evaluation index disease control rate of each experiment arm; calculating the anti-tumor rate of each experiment arm; and according to the disease control rate and the anti-tumor rate, sequencing drug effects of the different experiment arms. The method disclosed by the invention comprises steps of experiment mode selection, data quality control, data analysis and result demonstration, anda multi-layer and complete solving scheme is provided for PDX drug sensitivity analysis.

Description

technical field [0001] The invention relates to the fields of pharmacy and biostatistics, in particular to a drug sensitivity analysis method, an analysis system and an application thereof suitable for tumor transplantation models. Background technique [0002] Tumor xenograft model (Patient-derived xenograft, PDX) is a tumor model constructed by transplanting patient's tumor tissue into immunodeficient mice. PDX can maintain the original molecular, genetic, and tissue characteristics of tumor patients, as well as intra-tumor and inter-tumor heterogeneity (Reference 1). Existing studies have confirmed that the response of tumor patients to drugs is highly consistent with the response of corresponding PDX to drugs (References 2-4), which indicates that PDX has a wide range of applications in preclinical drug testing and personalized drug screening. Value. [0003] However, in order to ensure that PDX can play its role reliably, supporting drug susceptibility analysis tools ...

AI Technical Summary

Problems solved by technology

Compared with tumor cell line models, PDX models have obvious differences in biological characteristics (such as cell composition, genetic heterogeneity) and experimental techniques (such as measurement indicators), and the drug sensitivity analysis methods of tumor cell lines cannot be directly applied Based on PDX model (Document 4)

Compared with clinical trials, the differences in the indicators for evaluating drug efficacy and trial design (sample size, whether to consider tumor duplication, whether to consider intratumoral heterogeneity) and other aspects also hinder the application of clinical trial drug sensitivity analysis methods in PDX. (Document 5)

Images